i2o Therapeutics

About i2o Therapeutics

i2o Therapeutics is a private biotech company that emerged from groundbreaking research at Harvard University. The company focuses on developing innovative treatments for cardiometabolic diseases, which include conditions like diabetes and heart disease. One of their key innovations is the development of oral biologics delivery platforms. This means they are working on ways to deliver medications that are traditionally given by injection, like insulin, in pill form. This could significantly improve the patient experience by making treatments easier and less painful.

i2o Therapeutics serves a range of clients, primarily within the healthcare sector, including patients, healthcare providers, and pharmaceutical companies. The company operates in the biotech and pharmaceutical market, which is a highly specialized and competitive field. Their business model revolves around research and development (R&D) of novel peptides and peptide combinations, as well as proprietary delivery technologies. Peptides are short chains of amino acids that can act as drugs to treat various diseases.

The company aims to establish strategic partnerships to bring their innovations to market. These partnerships could be with larger pharmaceutical companies that have the resources to conduct large-scale clinical trials and distribute the final products. By forming these alliances, i2o Therapeutics can leverage the expertise and infrastructure of established players in the industry to accelerate the development and commercialization of their products.

i2o Therapeutics makes money through these strategic partnerships, licensing agreements, and potentially through the sale of their proprietary technologies and products once they receive regulatory approval. Their goal is to redefine patient care by providing more convenient and effective treatment options, thereby setting themselves apart from first-generation injectable treatments.